Philippe JEAN-PIERRE

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 04/04/2024
• Auteurs : Jean-Philippe GoiranCamille GonçalvesCécile VittoriGilles BrocardAdele BertiniMarco Leporati PersianoFabio CianchiAlessandro ConfortiGuillaume JouveLaurent MattioChristophe BenechLionel DarrasQuentin VitaleBrahimsamba BomouPierre SabatierMaxime DebretKevin JacqAnne-Lise DevelleChristine OberlinGilles van Heems
• Organismes : ARCHEORIENT - Environnements et sociétés de l'Orient ancien ARCHEORIENT - Environnements et sociétés de l'Orient ancien Laboratoire Image, Ville, Environnement ARCHEORIENT - Environnements et sociétés de l'Orient ancien Histoire et Sources des Mondes antiques ARCHEORIENT - Environnements et sociétés de l'Orient ancien Università degli Studi di Firenze = University of Florence = Université de Florence Region Toscane, Italie Oasi WWF Maremma Istituto per lo studio degli impatti Antropici e Sostenibilità in ambiente marino Exail (iXblue) Exail (iXblue) ARCHEORIENT - Environnements et sociétés de l'Orient ancien ARCHEORIENT - Environnements et sociétés de l'Orient ancien ARCHEORIENT - Environnements et sociétés de l'Orient ancien Études et valorisations archéologiques Institut des sciences de la terre [Lausanne] Environnements, Dynamiques et Territoires de Montagne Morphodynamique Continentale et Côtière Environnements, Dynamiques et Territoires de Montagne Laboratoire d'Informatique, Systèmes, Traitement de l'Information et de la Connaissance Environnements, Dynamiques et Territoires de Montagne Archéologie et Archéométrie Université Lumière - Lyon 2 Histoire et Sources des Mondes antiques Centre Alfred Ernout - Linguistique latine

---

Fichiers liés : Conférence Urbi et Orb_JournéesIMU2024.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/04/2024
• Auteurs : Wassilios MeissnerPhilippe RemyCaroline GiordanaDavid MaltêtePascal DerkinderenJean-Luc HouétoMathieu AnheimIsabelle BenatruThomas BoraudChristine Brefel-CourbonNicolas CarrièreHélène CatalaOlivier ColinJean-Christophe CorvolPhilippe DamierEstelle DellapinaDavid DevosSophie DrapierMargherita FabbriVanessa FerrierAlexandra Foubert-SamierSolène Frismand-KryloffAurore GeorgetChristine GermainStéphane GrimaldiClémence HardyLucie HopesPierre KrystkowiakBrice LaurensRomain LefaucheurLouise-Laure MarianiAna MarquesClaire MarseFabienne Ory-MagneVincent RigalleauHayet SalhiAmandine SaubionSimon StottClaire ThalamasClaire ThiriezFazia Mélissa TirRichard WyseAntoine BénardOlivier Rascol
• Organismes : Institut des Maladies Neurodégénératives [Bordeaux] CHU Henri Mondor [Créteil] Institut Mondor de Recherche Biomédicale Service de Neurologie [CHU Nice] Neuroendocrine, Endocrine and Germinal Differentiation Communication The Enteric Nervous System in gut and brain disorders [U1235] Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique CHU Limoges Hôpital de Hautepierre [Strasbourg] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Institut des Maladies Neurodégénératives [Bordeaux] Imagerie cérébrale et handicaps neurologiques Centre Hospitalier Régional Universitaire [CHU Lille] Institut du Cerveau = Paris Brain Institute Centre d’Investigation Clinique de Nantes Centre Hospitalier Universitaire de Toulouse Université Toulouse III - Paul Sabatier Centre d'investigation clinique de Toulouse Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'investigation clinique de Toulouse Centre Hospitalier Universitaire de Toulouse Emergence des Pathologies Virales Bordeaux population health Service de neurologie [Amiens] CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Bordeaux population health Service de neurologie [Amiens] Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 Bordeaux population health
• Publié dans New England Journal of Medicine le 29/10/2020

---

Résumé : Background: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.Methods: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent.Results: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%.Conclusions: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/04/2024
• Auteurs : Marianne AbifadelKaousar AhmmedSayera BanuIbrahima CamaraFahmida ChowdhuryDaouda CoulibalyGeorges DabarCédric DananchéRachel DawZakiul HassanMagali HervéAriful IslamFlorence Komurian-PradelJean-Pierre KouaméBourema KouribaJosette Najjar-PelletAndoniaina RakotonaivoFelana Ranaivo-RabetokotanyMandranto RasamoelinaTiavina RasolofoarisonMoussa RiachiMitra Saadatian-ElahiLuc SamisonValentina Sanchez PicotSita SavanéIsmaila TheraAbdoulaye TouréPhilippe Vanhems
• Organismes : Institut National de la Santé et de la Recherche Médicale International Centre for Diarrhoeal Disease Research, Bangladesh Laboratoire de Physique de l'Atmosphère et de l'Océan Siméon Fongang International Centre for Diarrhoeal Disease Research, Bangladesh Institut National de Santé Publique d'Abidjan-INSP Pôle de Santé Publique [Lyon] Hospices Civils de Lyon Santé publique, épidémiologie et écologie évolutive des maladies infectieuses [CIRI] Hospices Civils de Lyon Cardiovasculaire, métabolisme, diabétologie et nutrition Hospices Civils de Lyon Deakin University [Melbourne Burwood] Centre for Integrative Ecology School of Life and Environmental Sciences EcoHealth Alliance [New York] Centre International de Recherche en Infectiologie Fondation Mérieux Centre d'Infectiologie Clinique Charles Mérieux [Bamako, Mali] Centre Hospitalier Manara-Penitra Andohatapenaka [Antananarivo, Madagascar] Santé publique, épidémiologie et écologie évolutive des maladies infectieuses [CIRI] Hospices Civils de Lyon Santé publique, épidémiologie et écologie évolutive des maladies infectieuses [CIRI] Hospices Civils de Lyon
• Publié dans American Journal of Tropical Medicine and Hygiene le 25/10/2020

---

Résumé : ABSTRACT. Despite the numerous articles published on the clinical characteristics and outcomes of COVID-19 with regard to high-income countries, little is known about patients in low- and middle-income countries (LMIC) in this context. The objective of this observational, prospective, hospital-based multicentric study was to describe clinical features and outcomes of laboratory-confirmed COVID-19 patients hospitalized in each of the participating centers in Bangladesh, Guinea, Ivory Coast, Lebanon, Madagascar, and Mali during the first year of the pandemic (March 5, 2020 to May 4, 2021). The study outcome was the clinical severity of COVID-19, defined as hospitalization in intensive care unit or death. Multivariate logistic regression models were performed to identify independent variables associated with disease severity. Overall, 1,096 patients were included. The median age was 49.0 years, ranging from 38.0 in Mali to 63.0 years in Guinea. The overall clinical severity of COVID-19 was 12.3%, ranging from 6.4% in Mali to 18.8% in Guinea. In both groups of patients <60 and ≥60 years old, cardiovascular diseases (adjusted odds ratio [aOR]: 1.99; 95% CI: 1.13–3.50, P = 0.02; aOR: 2.47; 95% CI: 1.33–4.57, P = 0.004) were independently associated with clinical severity, whereas in patients <60 years, diabetes (aOR: 2.13; 95% CI: 1.11–4.10, P = 0.02) was also associated with clinical severity. Our findings suggest that COVID-19-related severity and death in LMICs are mainly driven by older age. However, the presence of chronic diseases can also increase the risk of severity especially in younger patients.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/04/2024
• Auteurs : Béatrice FerversOlivia PérolChristine LassetN MoumjidPauline VidicanPierre SaintignyJuliette TardyJulien BiaudetValérie BonadonaDominique TriviauxPhilippe MarijnenRodolf MongondryAnne Cattey-JavouheyRomain BuonoAmandine BertrandPerrine Marec-BérardChristine Rousset-JablonskiFrank PilleulVeronique ChristopheMagali GirodetDelphine PraudMarie-Laure SolodkyHugo CrochetAbdel AchacheMauricette MichalletChristelle GalvezAnne MiermontDamien SebileauPhilippe ZrounbaSophie BeaupèreThierry PhilipJean-Yves Blay
• Organismes : Centre Léon Bérard [Lyon] Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Parcours santé systémique Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre Léon Bérard [Lyon] Centre de Recherche en Cancérologie de Lyon Dynamiques du Cancer, adaptation et modélisation Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Research on Healthcare Performance Centre Léon Bérard [Lyon] Research on Healthcare Performance Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Centre de Recherche en Cancérologie de Lyon Centre Léon Bérard [Lyon] Research on Healthcare Performance Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] UNICANCER Institut Curie [Paris] Centre Léon Bérard [Lyon] UNICANCER Université Claude Bernard Lyon 1
• Publié dans Cancer Prevention Research le 23/10/2020

---

Résumé : This article describes some of the key prevention services in the Leon Berard Comprehensive Cancer Center (CLB) Lyon, France, which are based on clinical prevention services, outreach activities, and collaboration with professional and territorial health communities. In addition, research is embedded at all stages of the prevention continuum, from understanding cancer causes through to the implementation of prevention interventions during and after cancer. Health promotion activities in the community and dedicated outpatient primary cancer prevention services for individuals at increased risk have been implemented. The CLB's experience illustrates how prevention can be integrated into the comprehensive mission of cancer centers, and how in turn, the cancer centers may contribute to bridging the current fragmentation between cancer care and the different components of primary, secondary, and tertiary prevention. With increasing cancer incidence, the shift toward integrated prevention-centered cancer care is not only key for improving population health, but this may also provide a response to the shortage of hospital staff and overcrowding in cancer services, as well as offer opportunities to reduce carbon emissions from cancer care.

---

Fichiers liés : 133.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 02/04/2024
• Auteurs : Jean-Philippe MaguéJean-Pierre ChevrotTristan DumasLouise Tarrade
• Organismes : Institut Rhône-Alpin des systèmes complexes Interactions, Corpus, Apprentissages, Représentations LInguistique et DIdactique des Langues Étrangères et Maternelles Interactions, Corpus, Apprentissages, Représentations

---

Fichiers liés : GANESHs2024.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/04/2024
• Auteurs : Pierre-André JarrotAdrien MirouseSébastien OttavianiSimon CadiouJean-Hugues SalmonEric LiozonSimon ParreauMartin MichaudBenjamin TerrierPierre-Edouard GavandLudovic TrefondVirginie LavoiepierreJeremy KeraenDaniel RekassaBastien BouldoiresThierry WeittenDamien RocheAntoine PouletCaroline CharpinVincent GrobostMarion HermetMagali PallureChloe WackenheimLudovic KarkowskiPierre GrumetThomas RogierNabil BelkefiVincent PestreEmilie BroquetAmélie LeursSophie GautierValérie GrasPierre GiletJan HolubarNadia SivovaNicolas SchleinitzJean-Marc DurandBrice CastelAlexandre PetrierRobin ArcaniBaptiste GramontPhilippe GuilpainHubert LepidiPierre-Jean WeillerJoelle MicallefDavid SaadounGilles Kaplanski
• Organismes : Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research
• Publié dans Human Vaccines & Immunotherapeutics le 24/10/2020

---

Résumé :

---

Fichiers liés : 174 Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination Results from a nationwide survey.pdf

---

Source

---

• Type de publi. : Chapître d'ouvrage
• Date de publi. : 01/04/2024
• Auteurs : Antonio RomanoPhilippe Boula de MareüilJean-Pierre Lai
• Organismes : Laboratorio di Fonetica Sperimentale "Arturo Genre" Traitement du Langage Parlé - LISN GIPSA-Services GIPSA - SYstèmes Linguistiques, Dialectologie et Oralité

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2024
• Auteurs : Laure PonthierJulie AutmizguineBenedicte FranckAnders ÅsbergPhilippe OvetchkineAlexandre DesterePierre MarquetMarc LabriffeJean-Baptiste Woillard
• Organismes : Pharmacologie et Transplantation CHU Sainte Justine [Montréal] Université de Montréal Institut de recherche en santé, environnement et travail École des Hautes Études en Santé Publique Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Oslo University Hospital [Oslo] University of Oslo Université de Montréal Université Côte d'Azur Departement de Pharmacologie Clinique [CHU Nice] Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation Service de Pharmacologie, toxicologie et pharmacovigilance [CHU Limoges] Pharmacologie et Transplantation Service de Pharmacologie, toxicologie et pharmacovigilance [CHU Limoges]
• Publié dans Clinical Pharmacokinetics le 30/10/2020

---

Résumé : Background and objectives: Ganciclovir (GCV) and valganciclovir (VGCV) show large interindividual pharmacokinetic variability, particularly in children. The objectives of this study were (1) to develop machine learning (ML) algorithms trained on simulated pharmacokinetics profiles obtained by Monte Carlo simulations to estimate the best ganciclovir or valganciclovir starting dose in children and (2) to compare its performances on real-world profiles to previously published equation derived from literature population pharmacokinetic (POPPK) models achieving about 20% of profiles within the target.Materials and methods: The pharmacokinetic parameters of four literature POPPK models in addition to the World Health Organization (WHO) growth curve for children were used in the mrgsolve R package to simulate 10,800 pharmacokinetic profiles. ML algorithms were developed and benchmarked to predict the probability to reach the steady-state, area-under-the-curve target (AUC0-24 within 40-60 mg × h/L) based on demographic characteristics only. The best ML algorithm was then used to calculate the starting dose maximizing the target attainment. Performances were evaluated for ML and literature formula in a test set and in an external set of 32 and 31 actual patients (GCV and VGCV, respectively).Results: A combination of Xgboost, neural network, and random forest algorithms yielded the best performances and highest target attainment in the test set (36.8% for GCV and 35.3% for the VGCV). In actual patients, the best GCV ML starting dose yielded the highest target attainment rate (25.8%) and performed equally for VGCV with the Franck model formula (35.3% for both).Conclusion: The ML algorithms exhibit good performances in comparison with previously validated models and should be evaluated prospectively.

---

Fichiers liés : clean_article_clin_pk_gcv_1fev_corJBW.pdf

---

Source

---

• Type de publi. : Autre publication
• Date de publi. : 01/04/2024
• Auteurs : Ewen MullinsJean‐louis BressonTamas DalmayIan Crawford DewhurstMichelle EpsteinLeslie George FirbankPhilippe GuercheJan HejatkoFrancisco Javier MorenoHanspeter NaegeliFabien NoguéNils RostoksJose Juan Sánchez SerranoGiovanni SavoiniEve VeromannFabio VeronesiAna CamargoTilemachos GoumperisPaolo LenziPietro PiffanelliTommaso Raffaello
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans EFSA Journal le 01/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2024
• Auteurs : Marie MullerJulien BroséusAdrien GuilloteauStéphane WasseCatherine ThiéblemontStéphane NanceyGuillaume CadiotAurélien AmiotDavid LaharieSophie VieujeanYoram BouhnikChloé MartineauChristophe MichielsXavier HebuterneGuillaume SavoyeDenis FranchimontPhilippe SeksikLaurent BeaugerieMarc MaynadiéPierre FeugierLaurent Peyrin‐Biroulet
• Organismes : Service d'Hépato-gastro-entérologie [CHRU Nancy] Nutrition-Génétique et Exposition aux Risques Environnementaux Service d'Hématologie [CHRU Nancy] Equipe CADIR (LNC - U1231) Equipe CADIR (LNC - U1231) Hopital Saint-Louis [AP-HP] Hospices Civils de Lyon Autophagie infection et immunité - Autophagy Infection Immunity [CIRI] Centre International de Recherche en Infectiologie Hôpital universitaire Robert Debré [Reims] Service de gastro-entérologie [CHU Henri Mondor] Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier Universitaire de Liège Hôpital Beaujon [AP-HP] Hôpital Européen Georges Pompidou [APHP] Service d'Hépato-Gastro-Entérologie (CHU de Dijon) Centre Hospitalier Universitaire de Nice Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau Institute for Research and Innovation in Biomedicine Université de Rouen Normandie Service d'Hépato-Gastroentérologie [CHU Rouen] Hôpital Erasme = Erasmus Hospital = Erasmus Ziekenhuis CHU Saint-Antoine [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Equipe CADIR (LNC - U1231) Nutrition-Génétique et Exposition aux Risques Environnementaux Service d'Hématologie [CHRU Nancy] Nutrition-Génétique et Exposition aux Risques Environnementaux Service d'Hépato-gastro-entérologie [CHRU Nancy]
• Publié dans Journal of Crohn's and Colitis le 31/10/2020

---

Résumé : Abstract Background IBD is associated with an increased risk of developing lymphoma. Although recent data clarifies lymphoma epidemiology in IBD patients, clinical and pathological characteristics of lymphoma occurring in IBD remain ill-known. Methods Patients with IBD and lymphoma were retrospectively identified in the framework of a national collaborative study including the Groupe d’Étude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID) and the Lymphoma Study Association (LYSA). We characterized clinical and prognostic features for the 3 most frequent lymphoma subtypes occurring in IBD. We performed a multicentric case-control study. Controls (lymphoma de novo) were matched (5:1) to cases on gender, age at diagnosis, lymphoma subtype, year of diagnosis, IPI/FLIPI indexes. Overall survival (OS) and progression free survival were compared between cases and controls. Results 133 IBD patients with lymphoma were included (males = 62.4 %, median age at lymphoma diagnosis = 49 years in males ; 42 in females). Most had Crohn’s disease (73.7 %) and were exposed to thiopurines (59.4 %). The most frequent lymphoma subtypes were diffuse large B cell lymphoma (DLBCL, 45.1 %), Hodgkin lymphoma (HL, 18.8 %), and follicular lymphoma (FL, 10.5 %). When matched with 365 controls, prognosis was improved in IBD patients with DLBCL compared to controls (p = 0.0064, hazard ratio = 0.36) or similar (HL and FL). Conclusion Lymphomas occurring in IBD patients do not seem to have a worse outcome than in patients without IBD. Due to the scarcity of this situation, those patients should be managed in expert centers.

---

Source